{"gene":"ZKSCAN1","run_date":"2026-06-11T09:02:06","timeline":{"discoveries":[{"year":2014,"finding":"ZNF139 (ZKSCAN1) knockdown in gastric cancer cells reduced invasion and migration, accompanied by decreased expression and gelatinase activity of MMP-2 and MMP-9, decreased ICAM-1, and increased TIMP-1, indicating ZKSCAN1 regulates metastasis by modulating MMP-TIMP balance.","method":"siRNA knockdown, wound healing assay, Transwell assay, RT-PCR, Western blot, gelatin zymography","journal":"Neoplasma","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with specific molecular readouts (MMP activity, protein levels), single lab, multiple orthogonal methods","pmids":["24824930"],"is_preprint":false},{"year":2014,"finding":"ZNF139 (ZKSCAN1) knockdown in gastric cancer cells down-regulated MDR1/P-gp, MRP1, and Bcl-2 expression and up-regulated Bax, increasing chemosensitivity to 5-FU and L-OHP, establishing ZKSCAN1 as a regulator of multi-drug resistance via MDR-associated gene expression.","method":"siRNA transfection, MTT assay, RT-PCR, Western blot","journal":"Molecular biology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KD with defined molecular phenotype, single lab, multiple orthogonal methods","pmids":["24515389"],"is_preprint":false},{"year":2015,"finding":"ZNF139 (ZKSCAN1) knockdown in BGC823 gastric cancer cells induced apoptosis and G0/G1 arrest, with down-regulation of Survivin, xIAP, and Bcl-2, and up-regulation of caspase-3 and Bax, indicating ZKSCAN1 promotes apoptosis resistance through these apoptotic regulators.","method":"siRNA knockdown, flow cytometry (cell cycle, apoptosis), QPCR, Western blot","journal":"International journal of clinical and experimental pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined apoptotic readouts, single lab, multiple orthogonal methods","pmids":["26722429"],"is_preprint":false},{"year":2016,"finding":"ZNF139 (ZKSCAN1) knockdown in gastric cancer cells and tumor-bearing mice downregulated Bcl-2 and survivin, inhibiting cell viability and proliferation in vitro and tumor growth in vivo, confirming ZKSCAN1 promotes tumor growth via apoptosis pathway.","method":"siRNA knockdown, cell viability assay, Western blot, in vivo mouse tumor model","journal":"Oncology letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo loss-of-function with defined molecular readouts, single lab","pmids":["27698826"],"is_preprint":false},{"year":2018,"finding":"ZNF139 (ZKSCAN1) transcriptionally represses miR-185 promoter activity, as demonstrated by ChIP and dual-luciferase reporter assay; reduced miR-185 in turn promotes MDR gene expression (MDR1/P-gp, MRP-1, Bcl-2), establishing a ZNF139→miR-185 suppression axis in gastric cancer drug resistance.","method":"ChIP assay, dual-luciferase reporter assay, siRNA knockdown, cDNA overexpression, MTT assay, RT-PCR, Western blot","journal":"Bioscience reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct transcriptional repression shown by ChIP and reporter assay, single lab with two orthogonal methods","pmids":["30126848"],"is_preprint":false},{"year":2018,"finding":"miR-195-5p negatively regulates ZKSCAN1 (ZNF139) protein expression by binding to the 3'-UTR of ZNF139 mRNA, and silencing ZNF139 promotes chemosensitivity in gastric cancer cells, confirming ZKSCAN1 as a direct target of miR-195-5p in MDR regulation.","method":"Luciferase reporter assay (3'-UTR binding), Western blot, siRNA knockdown, MTT assay","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3'-UTR reporter assay plus functional validation, single lab","pmids":["29956811"],"is_preprint":false},{"year":2014,"finding":"ZNF139 (ZKSCAN1) knockdown by siRNA in BGC823 cells altered expression of proteins including FUSE-binding protein 1, HSP60, annexin A2/A7, and SUMO-1 activating enzyme, as identified by 2-D DIGE and LC-MS proteomics, linking ZKSCAN1 to regulation of proliferation, apoptosis, invasion, and adhesion-associated proteins.","method":"siRNA knockdown, 2-D fluorescence difference gel electrophoresis (2-D DIGE), LC-MS, Western blot","journal":"Hepato-gastroenterology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — proteomics screen identifies downstream proteins but does not establish direct regulatory mechanism; single lab, single study","pmids":["25436386"],"is_preprint":false},{"year":2025,"finding":"ZKSCAN1 forms a gene fusion (ZKSCAN1::MET) with MET kinase, generating an activating MET kinase fusion detected in Spitz melanocytoma; no other somatic mutations were identified outside MET, establishing ZKSCAN1 as a fusion partner that drives MET activation.","method":"Molecular profiling (next-generation sequencing/fusion detection) on tumor tissue","journal":"Journal of cutaneous pathology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single case report with molecular characterization; no functional reconstitution of the fusion protein","pmids":["40664441"],"is_preprint":false},{"year":2025,"finding":"ZKSCAN1::BRAF kinase fusion was overexpressed and found to signal in a fusion-dependent manner with paradoxical ERK phosphorylation in response to pan-RAF inhibitors; vertical RAF/MEK inhibition (LY3009120 + trametinib) resolved paradoxical activation and suppressed tumor growth.","method":"Overexpression of BRAF fusion constructs, ERK phosphorylation assays, inhibitor treatment, tumor growth assay","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — preprint, single lab, ZKSCAN1 is only one of several fusion partners tested; mechanistic details specific to ZKSCAN1::BRAF are limited","pmids":["bio_10.1101_2025.02.06.636895"],"is_preprint":true}],"current_model":"ZKSCAN1 (ZNF139) functions as a zinc finger transcription factor that promotes cell survival, invasion, and multi-drug resistance in cancer cells primarily by transcriptionally upregulating anti-apoptotic genes (Bcl-2, Survivin, xIAP) and MDR genes (MDR1/P-gp, MRP1) while suppressing pro-apoptotic Bax, and by transcriptionally repressing miR-185; it also regulates MMP-2/MMP-9 activity to control invasion, and can act as a fusion partner for MET or BRAF kinases, generating constitutively activating fusions."},"narrative":{"mechanistic_narrative":"ZKSCAN1 (ZNF139) is a zinc finger transcription factor that promotes gastric cancer cell survival, proliferation, invasion, and multi-drug resistance by coordinating the expression of apoptotic and drug-resistance gene programs [PMID:24515389, PMID:26722429, PMID:27698826]. Loss-of-function studies establish that ZKSCAN1 maintains apoptosis resistance by sustaining anti-apoptotic effectors (Bcl-2, Survivin, xIAP) while restraining pro-apoptotic Bax and caspase-3, such that its depletion triggers G0/G1 arrest and apoptosis in vitro and reduces tumor growth in vivo [PMID:26722429, PMID:27698826]. In parallel, ZKSCAN1 drives the multi-drug resistance phenotype by upregulating MDR1/P-gp and MRP1, with knockdown increasing chemosensitivity to 5-FU and L-OHP [PMID:24515389]. One transcriptional mechanism is direct: ZKSCAN1 binds and represses the miR-185 promoter, and the resulting drop in miR-185 derepresses MDR1/P-gp, MRP-1, and Bcl-2, defining a ZNF139→miR-185 axis in drug resistance [PMID:30126848]; ZKSCAN1 itself is held in check post-transcriptionally by miR-195-5p acting on its 3'-UTR [PMID:29956811]. ZKSCAN1 also controls metastatic behavior by shifting the MMP-TIMP balance, promoting MMP-2/MMP-9 expression and gelatinase activity and ICAM-1 while suppressing TIMP-1 [PMID:24824930]. Separately, ZKSCAN1 has been recovered as the 5' partner in oncogenic kinase fusions with MET in Spitz melanocytoma [PMID:40664441] and with BRAF [PMID:bio_10.1101_2025.02.06.636895].","teleology":[{"year":2014,"claim":"Established that ZKSCAN1 controls gastric cancer cell invasion and migration, identifying the MMP-TIMP axis as a downstream effector program rather than leaving its pro-metastatic role mechanistically unattributed.","evidence":"siRNA knockdown with wound healing, Transwell, RT-PCR, Western blot, and gelatin zymography in gastric cancer cells","pmids":["24824930"],"confidence":"Medium","gaps":["Does not show ZKSCAN1 binds MMP-2/MMP-9 or TIMP-1 promoters directly","Single lab, single cancer type","No in vivo metastasis readout"]},{"year":2014,"claim":"Linked ZKSCAN1 to the multi-drug resistance phenotype by showing its depletion lowers MDR1/P-gp, MRP1, and Bcl-2 and restores chemosensitivity, framing it as a regulator of drug-resistance gene expression.","evidence":"siRNA transfection with MTT chemosensitivity assay, RT-PCR, Western blot","pmids":["24515389"],"confidence":"Medium","gaps":["Direct vs indirect transcriptional control of MDR genes not resolved here","No demonstration of promoter occupancy","Single lab"]},{"year":2014,"claim":"An unbiased proteomic screen broadened the candidate effector set downstream of ZKSCAN1, but established correlation rather than direct regulation.","evidence":"siRNA knockdown with 2-D DIGE and LC-MS proteomics, Western blot in BGC823 cells","pmids":["25436386"],"confidence":"Low","gaps":["Screen identifies downstream proteins without establishing direct regulatory mechanism","Functional consequence of each altered protein untested","Single study"]},{"year":2015,"claim":"Resolved how ZKSCAN1 sustains survival by tying its loss to apoptosis and G0/G1 arrest through coordinated changes in Survivin, xIAP, Bcl-2, Bax, and caspase-3.","evidence":"siRNA knockdown with flow cytometry for cell cycle and apoptosis, QPCR, Western blot","pmids":["26722429"],"confidence":"Medium","gaps":["Direct transcriptional targets among these apoptotic regulators not identified","Single cell line","No promoter-binding evidence"]},{"year":2016,"claim":"Extended the survival role from culture to a tumor-bearing mouse model, confirming ZKSCAN1 promotes tumor growth via Bcl-2/survivin-dependent apoptosis suppression in vivo.","evidence":"siRNA knockdown with viability assays, Western blot, and in vivo mouse tumor model","pmids":["27698826"],"confidence":"Medium","gaps":["Knockdown durability and specificity in vivo not fully controlled","Mechanism upstream of Bcl-2/survivin not addressed","Single lab"]},{"year":2018,"claim":"Provided the first direct transcriptional mechanism for ZKSCAN1, showing it represses the miR-185 promoter to derepress MDR and anti-apoptotic genes, converting a correlative MDR role into a defined regulatory axis.","evidence":"ChIP and dual-luciferase reporter assays with siRNA/overexpression, MTT, RT-PCR, Western blot","pmids":["30126848"],"confidence":"Medium","gaps":["Exact ZKSCAN1 binding site on miR-185 promoter not mapped","Whether miR-185 fully accounts for MDR phenotype unquantified","Single lab"]},{"year":2018,"claim":"Placed ZKSCAN1 itself under upstream control by identifying miR-195-5p as a direct 3'-UTR regulator, situating it within a microRNA network governing chemoresistance.","evidence":"3'-UTR luciferase reporter assay with Western blot, siRNA knockdown, MTT","pmids":["29956811"],"confidence":"Medium","gaps":["Endogenous miR-195-5p regulation of ZKSCAN1 in patient tissue not shown","Single lab"]},{"year":2025,"claim":"Identified ZKSCAN1 as a structural fusion partner that can drive oncogenic kinase activation, distinct from its transcription-factor role, via a ZKSCAN1::MET fusion in Spitz melanocytoma.","evidence":"Next-generation sequencing / fusion detection on tumor tissue (single case report)","pmids":["40664441"],"confidence":"Low","gaps":["Single case report with no functional reconstitution of the fusion protein","Contribution of the ZKSCAN1 moiety to MET activation untested","No clinical follow-up of fusion-driven behavior"]},{"year":2025,"claim":"Showed that a ZKSCAN1::BRAF fusion signals in a fusion-dependent manner and exhibits paradoxical ERK activation resolvable by vertical RAF/MEK inhibition, indicating a therapeutically actionable kinase-fusion behavior.","evidence":"Overexpression of BRAF fusion constructs with ERK phosphorylation assays, inhibitor treatment, and tumor growth assay (preprint)","pmids":["bio_10.1101_2025.02.06.636895"],"confidence":"Low","gaps":["Preprint; ZKSCAN1 is only one of several fusion partners tested, so ZKSCAN1-specific contribution is limited","Endogenous occurrence of ZKSCAN1::BRAF not established","No structural basis for fusion-driven dimerization shown"]},{"year":null,"claim":"The direct genomic binding sites and full target repertoire of ZKSCAN1 as a transcription factor remain undefined, leaving open how it selects among apoptotic, MDR, and invasion gene programs.","evidence":"","pmids":[],"confidence":"Low","gaps":["No genome-wide binding map (ChIP-seq) for ZKSCAN1","Only miR-185 promoter shown as a direct target","Mechanism of how the same factor coordinates survival, MDR, and invasion programs unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[4]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[4]}],"localization":[],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2,3]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,4]}],"complexes":[],"partners":["MET","BRAF"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P17029","full_name":"Zinc finger protein with KRAB and SCAN domains 1","aliases":["Zinc finger protein 139","Zinc finger protein 36","Zinc finger protein KOX18"],"length_aa":563,"mass_kda":63.6,"function":"May be involved in transcriptional regulation","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P17029/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZKSCAN1","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ZKSCAN1","total_profiled":1310},"omim":[{"mim_id":"613774","title":"CALMODULIN-REGULATED SPECTRIN-ASSOCIATED PROTEIN 1; CAMSAP1","url":"https://www.omim.org/entry/613774"},{"mim_id":"608071","title":"F-BOX AND WD40 DOMAIN PROTEIN 4; FBXW4","url":"https://www.omim.org/entry/608071"},{"mim_id":"601260","title":"ZINC FINGER PROTEIN WITH KRAB AND SCAN DOMAINS 1; ZKSCAN1","url":"https://www.omim.org/entry/601260"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Nuclear bodies","reliability":"Approved"},{"location":"Mitochondria","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZKSCAN1"},"hgnc":{"alias_symbol":["KOX18","PHZ-37","ZSCAN33"],"prev_symbol":["ZNF139","ZNF36"]},"alphafold":{"accession":"P17029","domains":[{"cath_id":"1.10.4020.10","chopping":"53-132","consensus_level":"medium","plddt":80.7314,"start":53,"end":132},{"cath_id":"3.30.160.60","chopping":"377-459","consensus_level":"medium","plddt":91.2236,"start":377,"end":459}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P17029","model_url":"https://alphafold.ebi.ac.uk/files/AF-P17029-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P17029-F1-predicted_aligned_error_v6.png","plddt_mean":59.03},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZKSCAN1","jax_strain_url":"https://www.jax.org/strain/search?query=ZKSCAN1"},"sequence":{"accession":"P17029","fasta_url":"https://rest.uniprot.org/uniprotkb/P17029.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P17029/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P17029"}},"corpus_meta":[{"pmid":"28211215","id":"PMC_28211215","title":"ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways.","date":"2017","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28211215","citation_count":266,"is_preprint":false},{"pmid":"36691031","id":"PMC_36691031","title":"A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR.","date":"2023","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36691031","citation_count":113,"is_preprint":false},{"pmid":"32010565","id":"PMC_32010565","title":"Circ-ZKSCAN1 regulates FAM83A expression and inactivates MAPK signaling by targeting miR-330-5p to promote non-small cell lung cancer progression.","date":"2019","source":"Translational lung cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32010565","citation_count":87,"is_preprint":false},{"pmid":"29956811","id":"PMC_29956811","title":"miR‑195‑5p regulates multi‑drug resistance of gastric cancer cells via targeting ZNF139.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/29956811","citation_count":36,"is_preprint":false},{"pmid":"24824930","id":"PMC_24824930","title":"ZNF139 promotes tumor metastasis by increasing migration and invasion in human gastric cancer cells.","date":"2014","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/24824930","citation_count":35,"is_preprint":false},{"pmid":"30126848","id":"PMC_30126848","title":"ZNF139 increases multidrug resistance in gastric cancer cells by inhibiting miR-185.","date":"2018","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/30126848","citation_count":25,"is_preprint":false},{"pmid":"32454461","id":"PMC_32454461","title":"ZNF139/circZNF139 promotes cell proliferation, migration and invasion via activation of PI3K/AKT pathway in bladder cancer.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32454461","citation_count":21,"is_preprint":false},{"pmid":"24515389","id":"PMC_24515389","title":"Regulatory mechanism of ZNF139 in multi-drug resistance of gastric cancer cells.","date":"2014","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24515389","citation_count":18,"is_preprint":false},{"pmid":"37105934","id":"PMC_37105934","title":"CircRNA ZKSCAN1 promotes lung adenocarcinoma progression by miR-185-5p/TAGLN2 axis.","date":"2023","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37105934","citation_count":15,"is_preprint":false},{"pmid":"26722429","id":"PMC_26722429","title":"Silencing of ZNF139-siRNA induces apoptosis in human gastric cancer cell line BGC823.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26722429","citation_count":15,"is_preprint":false},{"pmid":"27698826","id":"PMC_27698826","title":"Effects of ZNF139 on gastric cancer cells and mice with gastric tumors.","date":"2016","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/27698826","citation_count":4,"is_preprint":false},{"pmid":"40664441","id":"PMC_40664441","title":"Congenital Spitz Melanocytoma With Activating ZKSCAN1::MET Kinase Fusion.","date":"2025","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40664441","citation_count":3,"is_preprint":false},{"pmid":"25436386","id":"PMC_25436386","title":"Comparative proteomics in gastric cancer cell line BGC823 after ZNF139 gene inhibited with RNA interference.","date":"2014","source":"Hepato-gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25436386","citation_count":2,"is_preprint":false},{"pmid":"40517173","id":"PMC_40517173","title":"Response to crizotinib in advanced intrahepatic cholangiocarcinoma with ZKSCAN1-MET fusion and MET amplification: case reports and literature review.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40517173","citation_count":1,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.02.06.636895","title":"Targeting BRAF kinase fusions with pan-RAF and vertical MAPK inhibition","date":"2025-02-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.06.636895","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9842,"output_tokens":2193,"usd":0.03121,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9264,"output_tokens":3372,"usd":0.06531,"stage2_stop_reason":"end_turn"},"total_usd":0.09652,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"ZNF139 (ZKSCAN1) knockdown in gastric cancer cells reduced invasion and migration, accompanied by decreased expression and gelatinase activity of MMP-2 and MMP-9, decreased ICAM-1, and increased TIMP-1, indicating ZKSCAN1 regulates metastasis by modulating MMP-TIMP balance.\",\n      \"method\": \"siRNA knockdown, wound healing assay, Transwell assay, RT-PCR, Western blot, gelatin zymography\",\n      \"journal\": \"Neoplasma\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with specific molecular readouts (MMP activity, protein levels), single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24824930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ZNF139 (ZKSCAN1) knockdown in gastric cancer cells down-regulated MDR1/P-gp, MRP1, and Bcl-2 expression and up-regulated Bax, increasing chemosensitivity to 5-FU and L-OHP, establishing ZKSCAN1 as a regulator of multi-drug resistance via MDR-associated gene expression.\",\n      \"method\": \"siRNA transfection, MTT assay, RT-PCR, Western blot\",\n      \"journal\": \"Molecular biology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KD with defined molecular phenotype, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24515389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ZNF139 (ZKSCAN1) knockdown in BGC823 gastric cancer cells induced apoptosis and G0/G1 arrest, with down-regulation of Survivin, xIAP, and Bcl-2, and up-regulation of caspase-3 and Bax, indicating ZKSCAN1 promotes apoptosis resistance through these apoptotic regulators.\",\n      \"method\": \"siRNA knockdown, flow cytometry (cell cycle, apoptosis), QPCR, Western blot\",\n      \"journal\": \"International journal of clinical and experimental pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined apoptotic readouts, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"26722429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZNF139 (ZKSCAN1) knockdown in gastric cancer cells and tumor-bearing mice downregulated Bcl-2 and survivin, inhibiting cell viability and proliferation in vitro and tumor growth in vivo, confirming ZKSCAN1 promotes tumor growth via apoptosis pathway.\",\n      \"method\": \"siRNA knockdown, cell viability assay, Western blot, in vivo mouse tumor model\",\n      \"journal\": \"Oncology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo loss-of-function with defined molecular readouts, single lab\",\n      \"pmids\": [\"27698826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZNF139 (ZKSCAN1) transcriptionally represses miR-185 promoter activity, as demonstrated by ChIP and dual-luciferase reporter assay; reduced miR-185 in turn promotes MDR gene expression (MDR1/P-gp, MRP-1, Bcl-2), establishing a ZNF139→miR-185 suppression axis in gastric cancer drug resistance.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter assay, siRNA knockdown, cDNA overexpression, MTT assay, RT-PCR, Western blot\",\n      \"journal\": \"Bioscience reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct transcriptional repression shown by ChIP and reporter assay, single lab with two orthogonal methods\",\n      \"pmids\": [\"30126848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-195-5p negatively regulates ZKSCAN1 (ZNF139) protein expression by binding to the 3'-UTR of ZNF139 mRNA, and silencing ZNF139 promotes chemosensitivity in gastric cancer cells, confirming ZKSCAN1 as a direct target of miR-195-5p in MDR regulation.\",\n      \"method\": \"Luciferase reporter assay (3'-UTR binding), Western blot, siRNA knockdown, MTT assay\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3'-UTR reporter assay plus functional validation, single lab\",\n      \"pmids\": [\"29956811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ZNF139 (ZKSCAN1) knockdown by siRNA in BGC823 cells altered expression of proteins including FUSE-binding protein 1, HSP60, annexin A2/A7, and SUMO-1 activating enzyme, as identified by 2-D DIGE and LC-MS proteomics, linking ZKSCAN1 to regulation of proliferation, apoptosis, invasion, and adhesion-associated proteins.\",\n      \"method\": \"siRNA knockdown, 2-D fluorescence difference gel electrophoresis (2-D DIGE), LC-MS, Western blot\",\n      \"journal\": \"Hepato-gastroenterology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — proteomics screen identifies downstream proteins but does not establish direct regulatory mechanism; single lab, single study\",\n      \"pmids\": [\"25436386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZKSCAN1 forms a gene fusion (ZKSCAN1::MET) with MET kinase, generating an activating MET kinase fusion detected in Spitz melanocytoma; no other somatic mutations were identified outside MET, establishing ZKSCAN1 as a fusion partner that drives MET activation.\",\n      \"method\": \"Molecular profiling (next-generation sequencing/fusion detection) on tumor tissue\",\n      \"journal\": \"Journal of cutaneous pathology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single case report with molecular characterization; no functional reconstitution of the fusion protein\",\n      \"pmids\": [\"40664441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZKSCAN1::BRAF kinase fusion was overexpressed and found to signal in a fusion-dependent manner with paradoxical ERK phosphorylation in response to pan-RAF inhibitors; vertical RAF/MEK inhibition (LY3009120 + trametinib) resolved paradoxical activation and suppressed tumor growth.\",\n      \"method\": \"Overexpression of BRAF fusion constructs, ERK phosphorylation assays, inhibitor treatment, tumor growth assay\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — preprint, single lab, ZKSCAN1 is only one of several fusion partners tested; mechanistic details specific to ZKSCAN1::BRAF are limited\",\n      \"pmids\": [\"bio_10.1101_2025.02.06.636895\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"ZKSCAN1 (ZNF139) functions as a zinc finger transcription factor that promotes cell survival, invasion, and multi-drug resistance in cancer cells primarily by transcriptionally upregulating anti-apoptotic genes (Bcl-2, Survivin, xIAP) and MDR genes (MDR1/P-gp, MRP1) while suppressing pro-apoptotic Bax, and by transcriptionally repressing miR-185; it also regulates MMP-2/MMP-9 activity to control invasion, and can act as a fusion partner for MET or BRAF kinases, generating constitutively activating fusions.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ZKSCAN1 (ZNF139) is a zinc finger transcription factor that promotes gastric cancer cell survival, proliferation, invasion, and multi-drug resistance by coordinating the expression of apoptotic and drug-resistance gene programs [#1, #2, #3]. Loss-of-function studies establish that ZKSCAN1 maintains apoptosis resistance by sustaining anti-apoptotic effectors (Bcl-2, Survivin, xIAP) while restraining pro-apoptotic Bax and caspase-3, such that its depletion triggers G0/G1 arrest and apoptosis in vitro and reduces tumor growth in vivo [#2, #3]. In parallel, ZKSCAN1 drives the multi-drug resistance phenotype by upregulating MDR1/P-gp and MRP1, with knockdown increasing chemosensitivity to 5-FU and L-OHP [#1]. One transcriptional mechanism is direct: ZKSCAN1 binds and represses the miR-185 promoter, and the resulting drop in miR-185 derepresses MDR1/P-gp, MRP-1, and Bcl-2, defining a ZNF139\\u2192miR-185 axis in drug resistance [#4]; ZKSCAN1 itself is held in check post-transcriptionally by miR-195-5p acting on its 3'-UTR [#5]. ZKSCAN1 also controls metastatic behavior by shifting the MMP-TIMP balance, promoting MMP-2/MMP-9 expression and gelatinase activity and ICAM-1 while suppressing TIMP-1 [#0]. Separately, ZKSCAN1 has been recovered as the 5' partner in oncogenic kinase fusions with MET in Spitz melanocytoma [#7] and with BRAF [#8].\",\n  \"teleology\": [\n    {\n      \"year\": 2014,\n      \"claim\": \"Established that ZKSCAN1 controls gastric cancer cell invasion and migration, identifying the MMP-TIMP axis as a downstream effector program rather than leaving its pro-metastatic role mechanistically unattributed.\",\n      \"evidence\": \"siRNA knockdown with wound healing, Transwell, RT-PCR, Western blot, and gelatin zymography in gastric cancer cells\",\n      \"pmids\": [\"24824930\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Does not show ZKSCAN1 binds MMP-2/MMP-9 or TIMP-1 promoters directly\",\n        \"Single lab, single cancer type\",\n        \"No in vivo metastasis readout\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linked ZKSCAN1 to the multi-drug resistance phenotype by showing its depletion lowers MDR1/P-gp, MRP1, and Bcl-2 and restores chemosensitivity, framing it as a regulator of drug-resistance gene expression.\",\n      \"evidence\": \"siRNA transfection with MTT chemosensitivity assay, RT-PCR, Western blot\",\n      \"pmids\": [\"24515389\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct vs indirect transcriptional control of MDR genes not resolved here\",\n        \"No demonstration of promoter occupancy\",\n        \"Single lab\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"An unbiased proteomic screen broadened the candidate effector set downstream of ZKSCAN1, but established correlation rather than direct regulation.\",\n      \"evidence\": \"siRNA knockdown with 2-D DIGE and LC-MS proteomics, Western blot in BGC823 cells\",\n      \"pmids\": [\"25436386\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Screen identifies downstream proteins without establishing direct regulatory mechanism\",\n        \"Functional consequence of each altered protein untested\",\n        \"Single study\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved how ZKSCAN1 sustains survival by tying its loss to apoptosis and G0/G1 arrest through coordinated changes in Survivin, xIAP, Bcl-2, Bax, and caspase-3.\",\n      \"evidence\": \"siRNA knockdown with flow cytometry for cell cycle and apoptosis, QPCR, Western blot\",\n      \"pmids\": [\"26722429\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct transcriptional targets among these apoptotic regulators not identified\",\n        \"Single cell line\",\n        \"No promoter-binding evidence\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended the survival role from culture to a tumor-bearing mouse model, confirming ZKSCAN1 promotes tumor growth via Bcl-2/survivin-dependent apoptosis suppression in vivo.\",\n      \"evidence\": \"siRNA knockdown with viability assays, Western blot, and in vivo mouse tumor model\",\n      \"pmids\": [\"27698826\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Knockdown durability and specificity in vivo not fully controlled\",\n        \"Mechanism upstream of Bcl-2/survivin not addressed\",\n        \"Single lab\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided the first direct transcriptional mechanism for ZKSCAN1, showing it represses the miR-185 promoter to derepress MDR and anti-apoptotic genes, converting a correlative MDR role into a defined regulatory axis.\",\n      \"evidence\": \"ChIP and dual-luciferase reporter assays with siRNA/overexpression, MTT, RT-PCR, Western blot\",\n      \"pmids\": [\"30126848\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Exact ZKSCAN1 binding site on miR-185 promoter not mapped\",\n        \"Whether miR-185 fully accounts for MDR phenotype unquantified\",\n        \"Single lab\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed ZKSCAN1 itself under upstream control by identifying miR-195-5p as a direct 3'-UTR regulator, situating it within a microRNA network governing chemoresistance.\",\n      \"evidence\": \"3'-UTR luciferase reporter assay with Western blot, siRNA knockdown, MTT\",\n      \"pmids\": [\"29956811\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Endogenous miR-195-5p regulation of ZKSCAN1 in patient tissue not shown\",\n        \"Single lab\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified ZKSCAN1 as a structural fusion partner that can drive oncogenic kinase activation, distinct from its transcription-factor role, via a ZKSCAN1::MET fusion in Spitz melanocytoma.\",\n      \"evidence\": \"Next-generation sequencing / fusion detection on tumor tissue (single case report)\",\n      \"pmids\": [\"40664441\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Single case report with no functional reconstitution of the fusion protein\",\n        \"Contribution of the ZKSCAN1 moiety to MET activation untested\",\n        \"No clinical follow-up of fusion-driven behavior\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed that a ZKSCAN1::BRAF fusion signals in a fusion-dependent manner and exhibits paradoxical ERK activation resolvable by vertical RAF/MEK inhibition, indicating a therapeutically actionable kinase-fusion behavior.\",\n      \"evidence\": \"Overexpression of BRAF fusion constructs with ERK phosphorylation assays, inhibitor treatment, and tumor growth assay (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.02.06.636895\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Preprint; ZKSCAN1 is only one of several fusion partners tested, so ZKSCAN1-specific contribution is limited\",\n        \"Endogenous occurrence of ZKSCAN1::BRAF not established\",\n        \"No structural basis for fusion-driven dimerization shown\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The direct genomic binding sites and full target repertoire of ZKSCAN1 as a transcription factor remain undefined, leaving open how it selects among apoptotic, MDR, and invasion gene programs.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No genome-wide binding map (ChIP-seq) for ZKSCAN1\",\n        \"Only miR-185 promoter shown as a direct target\",\n        \"Mechanism of how the same factor coordinates survival, MDR, and invasion programs unknown\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MET\", \"BRAF\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":6,"faith_total":6,"faith_pct":100.0}}